🇺🇸 FDA
Pipeline program

Tislelizumab 300 mg solution for injection, Tevimbra 100 mg concentrate for solution for infusion

BGB-A317-316

Phase 3 small_molecule active

Quick answer

Tislelizumab 300 mg solution for injection, Tevimbra 100 mg concentrate for solution for infusion for Locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma is a Phase 3 program (small_molecule) at Beone Medicines Ireland Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Beone Medicines Ireland Limited
Indication
Locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials